Caffeine and Sport Climbing Performance

NCT ID: NCT07333443

Last Updated: 2026-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-08

Study Completion Date

2025-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the effects of ingesting caffeine at a dose of 3 mg/kg body mass on pull-up performance and handgrip-related measures in trained climbers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction: Caffeine is widely recognized as a performance-enhancing substance across numerous athletic disciplines; however, its role in sport climbing has received comparatively limited scientific attention. Because climbing performance relies heavily on grip force, explosive upper-body strength, and localized muscular endurance, this investigation evaluated the short-term impact of a low caffeine dose on climbing-relevant performance outcomes.

Objective: To determine the effects of ingesting caffeine at a dose of 3 mg/kg body mass on pull-up performance and handgrip-related measures in trained climbers.

Methods: Thirteen trained young male climbers participated in a triple-blind, randomized, crossover study design, completing two experimental conditions (caffeine and placebo). Performance assessments included a pull-up one-repetition maximum (1RM), a pull-up power test conducted at multiple external loads, a pull-up endurance test, and several grip performance evaluations, namely maximal dead-hang duration, maximal dead-hang force, and rate of force development (RFD).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Climbing Caffeine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

A triple-blind, randomized, placebo-controlled design
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Participants, investigators and statistician

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

0 mg/kg of caffeine

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Placebo supplementation was provide to young male climbers.

Caffeine

3 mg/kg of caffeine

Group Type EXPERIMENTAL

Acute and moderate dose of caffeine (3 mg/kg body mass)

Intervention Type DIETARY_SUPPLEMENT

Caffeine supplementation was provide to young male climbers.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acute and moderate dose of caffeine (3 mg/kg body mass)

Caffeine supplementation was provide to young male climbers.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo supplementation was provide to young male climbers.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy individuals
* Age between 18 and 40 years
* At least three months of continuous climbing practice
* Ability to hang for at least 5 seconds from an 18-mm edge
* Ability to perform at least one strict body-weight pull-up

Exclusion Criteria

* Any musculoskeletal or medical condition preventing completion of the experimental protocol
* Participation in less than three training sessions per week or a total training volume \<150 min/week
* Use of medications or dietary supplements known to affect caffeine metabolism
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Alcala

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alberto Pérez-López

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alberto Pérez López, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Alcala

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

Alcalá de Henares, Madrid, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CEIP/2024/5/117

Identifier Type: OTHER

Identifier Source: secondary_id

CEIP/2024/5/117

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Caffeine and Intermittent Claudication
NCT00388128 COMPLETED PHASE3
Energy Drinks & Driving Ability
NCT01007877 COMPLETED NA
Effect of Caffeine on Fetal Growth
NCT00131690 COMPLETED PHASE4